Clinical Trial: NCT06881940
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
Status:
NOT YET RECRUITINGPhase:
Not Applicable| Lead Sponsor: | Instituto Nacional de Cardiologia Ignacio Chavez |
| Information Provided By: | Instituto Nacional de Cardiologia Ignacio Chavez |
| Last Update Posted: | 2025-03-18 |
Study Overview
Brief Summary
This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with anthracyclines and/or trastuzumab through a randomized, active control group, open-label clinical trial.
Official Title
Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial
Conditions
Cancer Therapy-Related Cardiac Dysfunction
Intervention / Treatment
- Other: Rehabilitation Program
- Other: No Rehabilitation Program
Other Study ID Numbers
- 24-1488
Start Date (Estimated)
2025-04-01
Primary Completion Date (Estimated)
2028-12-01
Study Completion Date (Estimated)
2029-12-01
Enrollment (Estimated)
284
Study Type
Interventional
Phase
Not Applicable
| Lead Sponsor: | Instituto Nacional de Cardiologia Ignacio Chavez |
| Information Provided By: | Instituto Nacional de Cardiologia Ignacio Chavez |
| Last Update Posted: | 2025-03-18 |
Study Overview
Brief Summary
This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with anthracyclines and/or trastuzumab through a randomized, active control group, open-label clinical trial.
Official Title
Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial
Conditions
Cancer Therapy-Related Cardiac Dysfunction
Intervention / Treatment
- Other: Rehabilitation Program
- Other: No Rehabilitation Program
Other Study ID Numbers
- 24-1488
Start Date (Estimated)
2025-04-01
Primary Completion Date (Estimated)
2028-12-01
Study Completion Date (Estimated)
2029-12-01
Enrollment (Estimated)
284
Study Type
Interventional
Phase
Not Applicable